MarketPulse

Phase 2

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Apogee Therapeutics to Unveil 52-Week Phase 2 Data for APG777 Atopic Dermatitis Treatment

Apogee Therapeutics to present 52-week Phase 2 data for APG777 in atopic dermatitis on March 23, 2026, signaling major clinical development milestone.
APGEbiologicsatopic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Jade Biosciences, Inc.

Jade Biosciences Posts $127.4M Loss, Eyes 2028 Cash Runway With Pipeline Catalysts

Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.
JBIOmonoclonal antibodyclinical trials